Medical network - April 18 in the industry point of view, the reference case last year, this year still down is expected to "block halved. While in the back of a national negotiations, shows more and more multinational companies in China, the change of the "rich" strategy, is willing to lower figure "to the price change amount" insurance market. 

 

Recently, people club department issued by the general office of human resources and social security ministry about 2017 national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue range of circular negotiations, sure will be 44 species included in the 2017 national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue negotiations. 

 

Part of the "word of mouth medicine" 

 

Specific view, if the variety is imported or domestic, this time into the negotiation imports reached 24 varieties, domestic varieties for 20; If the treatment area, involved a total of more than ten aspects, such as anti-tumor, cardiovascular, anti-tumor and immune modulators of species number 22 half of the total number of varieties, involved anti-tumor medicine market scale of nearly one hundred million yuan, which is shown in the current our country under the background of a high incidence of major diseases such as tumor, health policy for the reimbursement for use is more and more attention, is willing to tilt. 

 

"From the point of drug list, including mesylate path for Nepal, toluene sulfonic acid sorafenib pills, hydrochloric acid, pieces and cover for it late stage of common tumor such as lung cancer, gastric cancer treatment using the star of the drug. These 'word of mouth medicine has curative effect good, the price is high, and zero reimbursement problems, lead to cancer patients family carry a lot of economic burden." A industry observers said, due to tumor drug prices, imports because of sickness poor family. 

 

Decline is expected to "stop by" 

 

"Although China's access to health care medicine negotiation mechanism at the exploration stage, but in expanding the scope of speed, can feel process." Last year the industry observers said to negotiations, drug price reduction efforts finally reached 54% ~ 67%, this year's strength greatly will refer to the last drop. 

 

"Early years relevant departments of the imported drugs price reduction is drizzle, some reduction to 10% ~ 15%, and only when the multinational pharmaceutical companies in China is very strong, your breath had to face a little concessions." The observers, according to the current domestic medical market to import the original drug prices remained high, because of the lack of market competition, the international prevailing practice is adopted unified negotiation, reduce the high prices to a reasonable range. 

 

And national negotiations are able to make some drug firms achieve bigger reduction, part depends on the multinational pharmaceutical companies in China have passed "lay money" high-speed development period. "Their products face patent expiring, if you don't reduce the price, the future is likely to jianghu status not protect; plus reimbursement the huge temptation, appropriate 'price for quantity can achieve sales." It said. 

 

In addition, the shortlisted for the negotiation of domestic medicine also includes A lot of a-share listed companies fist products, such as tasly, for both are the product selected. "Once negotiated, help product channels to achieve sales of blowout in a hospital." The personage inside course of study says, in particular, some highly profitable proprietary Chinese medicine products, possible can get huge market space, is advantageous to the listed company sales promotion.